Proactive - Interviews for investors

Andean Precious Metals CFO Juan Carlos Sandoval joined Steve Darling from Proactive from our OTC studio in New York City about the company’s recent acquisition of the Golden Queen gold mine in California, which produces 60,000 ounces of gold annually. Sandoval emphasized the mine’s significant exploration potential, with the company investing $20 million in capital expenditures (CapEx) to enhance operations. This investment includes fleet replacements and exploration efforts aimed at improving the mine’s overall output.

In addition to expanding operations in California, Sandoval highlighted the company’s strategic decision to diversify beyond Bolivia, where it operates a processing facility handling third-party ore. This move is part of a broader effort to reduce risk and increase focus on the North American market, while still benefiting from Bolivia's robust silver production. "Bolivia has been great for us, but diversifying into the U.S. was necessary for our investors," Sandoval stated.

Looking forward, Andean Precious Metals aims to grow by optimizing its current operations and exploring additional resources at Golden Queen. With strong commodity prices, no debt on its balance sheet, and a solid financial position, the company is well-positioned for continued success in the mining sector.

#proactiveinvetors #andeanpreciousmetalscorp #tsxv #apm #otcqx #anpmf

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Giyani Metals Corp CEO Charles FitzRoy joined Steve Darling from Proactive to provided an exciting update on the company's Demo Plant, which is advancing towards the commissioning phase. Key milestones include the successful commissioning of the steam boiler, air supply system, and demineralized water plant, as well as the installation of the Yokogawa Distributed Control System, which powers the control room. The DCS is crucial for operating the Demo Plant as a continuous process flow, rather than batch operations, marking a significant step forward in the production of battery-grade manganese.

FitzRoy highlighted that the Demo Plant remains on track for commissioning and production of up to 600 kg per day of High-Purity Manganese Sulphate Monohydrate by Q4 2024. The continuous process flow is a strategic advantage, ensuring steady-state operations that consistently meet the product specification required by offtake partners. HPMSM produced will be tested and qualified by these partners, and the installation of an ISO-certified independent laboratory is underway to ensure product quality and consistency.

This facility will not only optimize production processes but also refine the engineering design and reduce both operating costs and carbon footprints. The Demo Plant is key in Giyani's efforts to secure offtake agreements and is running in parallel with the company’s Definitive Feasibility Study, slated for completion in 2025. The company plans to keep the market updated as the Demo Plant progresses through commissioning and production phases.

#proactiveinvestors #giyanimetalscorp #tsxv #emm #charlesfitzroy #mining

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Genflow Biosciences Plc CEO Dr. Eric Leire joined Steve Darling from Proactive to share news the company has announced it has secured €4,026,525 in non-dilutive financial support from the Wallonia region, which will aid in the development of Genflow’s lead gene therapy, GF-1002. This therapy is being developed for the treatment of Metabolic Associated Steatohepatitis (MASH), a severe liver disease. The Wallonia region's financial backing demonstrates the recognition of Genflow's pioneering work in gene therapy.

Dr. Leire explained that the support includes a non-reimbursable research grant covering 70% of Genflow’s research expenses and a recoverable advance funding 55% of the development costs, which will be repaid upon the commercialization of GF-1002. This funding is expected to cover three years of development, and Genflow plans to secure the remaining funds required to fulfill its share of the project over this period. This marks a significant step forward in the fight against MASH, as the company progresses towards bringing a potential new treatment to market.

#proactiveinvestors #genflowbioscienecesplc #lse #genf #otcqb #genff

#GenflowBiosciences #MASH #GF1002 #ClinicalTrials #BiotechFunding #LongevityScience #WalloniaRegion #GMP #Biopharma

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Rainbow Rare Earths CEO George Bennett joined Steve Darling from Proactive to share updates on the company’s impressive progress for the year ended June 30, 2024. Pilot operations at the Phalaborwa Rare Earths Project in South Africa have successfully produced two valuable products: a mixed rare earth carbonate and separated neodymium and praseodymium oxide with a purity of around 96%. This breakthrough marks the first commercial recovery of rare earth elements from phosphogypsum, a byproduct of phosphate mining.

With the process for separating neodymium and praseodymium nearing optimization, the company will shift its focus to separating other rare earth elements such as dysprosium and terbium, crucial for the production of green energy technologies like electric vehicles and wind turbines.

Rainbow also announced talks with potential off-takers (end users), a key step toward securing project financing for the Phalaborwa operation, which is slated for opening in 2027. This announcement follows the receipt of a $50 million investment proposal from the US International Development Corporation and a royalty and placement agreement with mining fund Ecora, strengthening the company's financial position.

Rainbow maintains a healthy cash reserve of $9.7 million. The Phalaborwa project holds 35 million tonnes of mineral resources with a concentration of 0.44% total rare earth oxides (TREO), making it a vital asset in the growing global demand for rare earths. The market for rare earth permanent magnets, driven by green energy technologies, has doubled since 2020, with demand expected to continue rising by 7% annually over the next decade.

#proactiveinvestors #rainbowrareearthslimited #lse #rbw #otc #rbwrf

#RainbowRareEarths #PhalaborwaProject #RareEarthsSeparation #GeorgeBennett #EnergyTransition #RareEarthOxides #SustainableMining #CriticalMinerals #RareEarthMetals #TechMet #ProactiveInvestments#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Vivos Therapeutics CEO Kirk Huntsman joined Steve Darling from Proactive to discuss significant milestone with the FDA clearance of their oral appliance for treating obstructive sleep apnea (OSA) in children aged 6 to 17, particularly those requiring orthodontic treatment. This marks the first time an oral appliance has been approved for treating moderate to severe OSA in this pediatric group.

Huntsman pointed out that around 20% of children in this age range suffer from OSA or related sleep disorders, which can lead to serious developmental and behavioral challenges like stunted growth, attention problems, and reduced IQ. The new device offers an alternative to traditional treatments such as surgery, which often fail to provide lasting results.

In addition to this milestone, Vivos Therapeutics has also achieved another regulatory victory, securing new CPT medical codes from the American Medical Association (AMA) for all Vivos CARE oral medical devices. These codes, set to take effect on January 1, 2025, will make OSA treatments more accessible and affordable by improving the exchange of standardized information in healthcare. This approval comes after Vivos had earlier gained Medicare coverage for their devices, further expanding the availability of their treatment to children.

With the new CPT codes, Vivos aims to enhance patient care, outcomes, and reduce costs, positioning the company to significantly expand its mission of making OSA treatments more widely available across the U.S.

#proactiveinvestors #vivostherapeuticsinc #nasdaq #vvos #sleepapnea#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews #PediatricOSA #SleepApneaTreatment #KirkHuntsman #FDAApproval #HealthcareInnovation #ChildrensHealth #ObstructiveSleepApnea #MedicalBreakthrough #OrthodonticCare #ProactiveInvestors #HealthTech

U.S. Global Investors CEO Frank Holmes joined Steve Darling from Proactive to share insights on the airline industry’s performance and future potential during an interview with Proactive. Highlighting the rebound in airline stocks, particularly through the Jets ETF, Holmes emphasized the strong revenue growth seen across the industry. Even with recession concerns, ticket prices have remained high, suggesting sustained demand.

Holmes also discussed strategic moves within the sector, such as United Airlines' stock buyback and Elliott Management’s investment in Southwest Airlines, reflecting strong investor confidence. He noted that airline stocks continue to trade at a significant discount relative to the broader market, despite record travel numbers. According to Holmes, this positions the industry for potential upside in terms of both revenue and cash flow.

The Jets ETF, which provides exposure to global airlines and even airports, offers investors a unique opportunity to tap into the ongoing growth of the airline industry.

#proactiveinvestors #usglobalinvestorsinc #nasdaq #grow #etf #jets #travel #colombia #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Ananda Developments Finance Director Jeremy Sturgess-Smith joined Steve Darling from Proactive to announce significant advancements for the company. Two of Ananda’s patent-pending cannabinoid medicines, MRX2 and MRX2T, will be used in two Phase IIIa epilepsy clinical trials, co-funded by the National Institute for Health and Care Research (NIHR) and the NHS. The trials, conducted by investigators at University College London and Great Ormond Street Hospital, will involve up to 500 patients and represent the world’s first double-blind randomized controlled trials to investigate the combined use of cannabidiol (CBD) and tetrahydrocannabinol (THC) for epilepsy. These will also be the first to evaluate such treatments for both children and adults with difficult-to-treat epilepsies.

Sturgess shared that the MRX formulations will serve as the investigational medicinal products for these ground-breaking trials, which aim to support a marketing authorization application for MRX2 and MRX2T. Should the trials yield positive results, Ananda plans to advance further regulatory and commercial development activities for these medicines.

The trials will assess the safety and efficacy of the specific cannabidiol and CBD plus THC formulations in patients suffering from two forms of treatment-resistant epilepsy. Favorable results could pave the way for submission to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and other regulatory bodies, moving Ananda one step closer to introducing innovative cannabinoid treatments for epilepsy.

#proactiveinvestors #anandadevelopmentsplc #aqse #ana

#EpilepsyResearch #CannabinoidMedicine #ClinicalTrials #CBDTherapy #PharmaInnovation #NIHR #Healthcare #EpilepsyTreatment#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Sunstone Metals Ltd (ASX:STM) managing director Patrick Duffy joins Proactive’s Tylah Tully to discuss the maiden mineral resource estimate (MRE) for the El Palmar gold-copper porphyry project in northern Ecuador.

The initial estimate from the T1 deposit records 1.2 million ounces of gold equivalent (AuEq), establishing a solid foundation for future exploration. The resource is at surface level and suitable for open-pit mining.

T1 deposit contains 64 million tonnes of ore with a grade of 0.60 g/t AuEq, including 0.41 g/t gold, 0.13% copper and 0.7 g/t silver. The MRE was derived from 17,699 metres of drilling.

Sunstone Metals has also set an exploration target of 1.0 to 1.2 billion tonnes with the potential for 10 to 27 million ounces of gold and 1 to 3.7 million tonnes of copper.

Duffy emphasised the potential for El Palmar to join the ranks of Tier-1 deposits, with similarities to Solgold's Cascabel Alpala and Codelco's Llurimagua deposits in the same region.

Early-stage testing shows favourable recovery rates, with gold recovery at 90% and copper at 78%. Ongoing drilling and discussions with strategic partners aim to unlock further value from the project.

#ProactiveInvestors #SunstoneMetals #ASX #ElPalmar #GoldCopper #PorphyryProject #MiningExploration #MineralResource #Tier1Discovery #EcuadorMining #OpenPitMining #ExplorationTarget #MetallurgicalTesting #GoldPrices #CopperMining #StrategicPartners #ResourceExpansion #MRE #GoldCopperDiscovery #MiningPotential #PorphyryDeposit #MineralExploration

Firebird Metals Ltd (ASX:FRB, OTC:FRBMF) managing director Peter Allen joins Proactive’s Tylah Tully to discuss successful trials using a pilot-scale calcining rotary kiln at the Hunan Firebird Battery Technologies Plant, Hunan Province, China.

The trials demonstrate significant energy savings, supporting Firebird's efforts in producing low-cost, high-purity manganese sulphate for lithium manganese iron phosphate (LMFP) batteries.

The self-developed electrical rotary kiln showed a 70% reduction in energy consumption, using 80-100 kWh per tonne compared to more than 300 kWh for conventional kilns. This leads to cost reductions of approximately US$30 per tonne, or 5% of total production costs.

The testing was conducted in partnership with Sunward, a Chinese rotary tunnel kiln producer, who co-funded the energy-saving calcining unit.

The kiln, installed at the Jinshi High-Tech Industrial Park, is scalable and is expected to deliver further savings as production expands.

Firebird aims to improve its cost profile while progressing towards full-scale production with potential for the kiln to be used in other industries.

The company has begun designing higher temperature kilns for applications such as lithium spodumene processing and has initiated international patenting of its kiln technology.

#Proactiveinvestors #FirebirdMetals #ASX #ManganeseSulphate #BatteryTech #EnergyEfficiency #RotaryKiln #CostReduction #SustainableMining #ChinaManufacturing #LMFPBatteries #PilotKiln #Sunward #CalciningTechnology #IndustrialProduction #BatteryMaterials #HighPurityManganese #MiningInnovation #MineralProcessing #KilnTechnology #LithiumSpodumene #PatentPending

Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest company news from Sovereign Metals Ltd (ASX:SVM, OTC:SVMLF, AIM:SVML).

It has completed an infill drilling program at its Kasiya Rutile-Graphite Project in Malawi. The program aimed to upgrade the mineral resource estimate (MRE) and convert probable ore reserves to the proven category.

Kasiya is the world’s largest rutile deposit and the second-largest flake graphite deposit, with more than 66% of the current MRE in the indicated category.

The drilling program included 281 aircore holes, 309 hand auger holes and 30 push tube and diamond core holes. An offset spacing of 200x200 metres was used for better geological analysis.

Samples will be assayed in laboratories in South Africa and Australia, with results expected in early 2025.

The southern Kasiya pits, which are expected to provide ore for the first eight years of production, were the focus of the drilling. It is expected that the MRE will be upgraded from indicated to measured and reserves will be converted from probable to proven under the JORC Code.

Rutile mineralisation is concentrated near the surface, while graphite grades improve at depths below 4 metres.

#ProactiveInvestors #SovereignMetals #ASX #OTC #AIM #JusttheFacts #KasiyaProject #Rutile #Graphite #Mining #Malawi #ResourceUpgrade #InfillDrilling #AircoreDrilling #GraphiteMining #RutileDeposit #MineralResources #DrillingProgram #JORCCode #MiningIndustry #GraphiteAssay #RutileAssay #TechnicalStudies #OreReserves #ResourceEstimate